



Xellia Pharmaceuticals receives Industrial Research and Innovation (IRI) Grant to support the development of Value-Added Medicines (VAM) in the antibiotics space

Xellia Pharmaceuticals commences project on the development of liquid antibiotics and active substances with antibiotic-like stabilization mechanisms for intravenous and intramuscular application

Zagreb, Croatia and Copenhagen, Denmark, 28 April 2021 - Xellia Pharmaceuticals ('Xellia'), a global leader in the manufacturing of specialty anti-infective treatments, announces it has received an Industrial Research and Innovation (IRI) Grant from the Croatian Ministry of Economy and Sustainable Development and the Agency for SMEs, Innovations and Investments, co-financed by the European Union from the European Regional Development Fund, for its Zagreb R&D Center-of-Excellence (Xellia d.o.o, Croatia) to work on the implementation of the project "Development of liquid antibiotics and active substances with antibiotic-like stabilization mechanisms for intravenous and intramuscular application". The implementation period commenced on February 17th 2020 and will run until August 17th 2023. During this period the project will receive a total contribution of financing from the EU of 22.940.363,56 HRK (3.606.280 USD). Total project value is estimated at 50.601.263,82 HRK (7.954.635,41 USD).

With the project, Xellia is aiming to develop new liquid RTU (Ready-To-Use) formulations of value-added medicines in the antibiotics space, with stabilization mechanisms for intravenous and intramuscular application, based on the stabilization of the active substance in a solution, and to enable the development of the STABSOL platform as a key technology for accelerated drug development.

Through the stages of industrial research and experimental development, Xellia aims to develop advanced formulations for intravenous and intramuscular use for the global market and will work to develop technology for a systematic and accelerated process of research and development of formulations suitable for parenteral application based on drug stabilization. The improved formulations of the value-added medicines that are expected to be developed as a result of the project will aim to reduce medical error, microbiological contamination, and address the global problem of antimicrobial resistance (AMR), as well as aim at reducing the overall financial impact of antibiotic treatments.

Over recent years Xellia has had significant investment in R&D; creating a platform to enable the development of an innovative pipeline of value-added anti-infective therapies. Longer term, it is Xellia's ambition to provide more clinically differentiated products, through the investigation of optimization and repurposing of existing anti-infective therapies; to increase efficacy and reduce harmful side effects such as those caused by toxicity.

Chief Scientific Officer, Xellia Pharmaceuticals, Dr. Aleksandar Danilovski, said, "We invest significantly in R&D and are dedicated to preserving the safety and long-term effectiveness of existing anti-infectives by developing and commercializing safer, easier to use and more efficient new value-added medicines. This project is in line with our ambition to bring more

innovative ready-to-use products to the market, and our overall mission to develop new delivery solutions of critical-care anti-infectives that can address patients' unmet needs."

Carl-Åke Carlsson, CEO of Xellia, added, "We are grateful for this Grant and the acknowledgment it brings to our innovation and development of value-added anti-infective treatments. With Xellia's focused R&D capabilities within this area, through the support of the Grant, I am convinced we can make substantial progress in this important project - working towards Xellia's purpose, to save and enhance lives by leading the fight against infections."

- Ends -

*The project is co-financed by the European Union from the European Regional Development Fund.

*The content of the website is the sole responsibility of Xellia Pharmaceuticals ApS.

For more information, please contact:

Xellia Pharmaceuticals

Dr Aleksandar Danilovski, CSO

Tel: +45 32 64 55 00

Instinctif Partners (International media relations)

Melanie Toyne-Sewell / Rozi Morris / Siobhan Sanford

Tel: +44 (0) 20 7457 2020

Email: xellia@instinctif.com

About Xellia Pharmaceuticals

Xellia Pharmaceuticals ("Xellia") is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections.

With over 115 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable products. Continuing the Company's evolution, Xellia is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease of use for healthcare professionals.

Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East and North America. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,800 people.

Further information about Xellia can be found at: www.xellia.com. Connect with us on [LinkedIn](#).

More information:

www.strukturnifondovi.hr

www.strukturnifondovi.hr/eu-fondovi/esi-fondovi-2014-2020/op-konkurentnost-i-kohezija/